The effects of the IRA on our business and the healthcare industry in general is not yet known.
All entries for: Biologic
March 12, 2026
Precision Biosciences Inc
Neutral Outlook
Durham, NC
51-200 employees
While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Antiviral, Hematology, Immune Diseases, Infectious Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic
March 12, 2026
Theriva Biologics, Inc.
Negative Outlook
Rockville, MD
1-50 employees
Although full economic effect of the IRA on our business and the pharmaceutical industry in general is unknown at this time, it will likely have a significant impact on the pharmaceutical industry and the pricing of our products and product candidates.
Disease Area: Infectious Diseases, Oncology, Rare Diseases
Drug Type: Biologic
March 12, 2026
Whitehawk Therapeutics, Inc.
Neutral Outlook
Morristown, NJ
1-50 employees
In August 2022, Congress passed the Inflation Reduction Act of 2022 (the “Inflation Reduction Act”), which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries
Disease Area: Oncology
Drug Type: Biologic
March 11, 2026
Tenaya Therapeutics, Inc.
Neutral Outlook
South San Francisco, CA
51-200 employees
While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.
Disease Area: Cardiology, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
March 11, 2026
Verrica Pharmaceuticals Inc.
Neutral Outlook
West Chester, PA
51-200 employees
It is unclear how such challenges and the healthcare reform measures of the current administration will impact the ACA and our business.
Disease Area: Dermatology, Infectious Diseases, Oncology
Drug Type: Biologic, Small Molecule
March 11, 2026
Horizon Therapeutics/MD
Layoffs
Rockville, MD
1,001-5,000 employees
Amgen subsidiary Horizon Therapeutics is laying off 22 employees from its Rockville, Maryland site, effective May 8, according to a WARN Act notice.
Disease Area: Rare Diseases
Drug Type: Biologic, Small Molecule